Sublingual  ||| S:0 E:11 ||| JJ
immunotherapy  ||| S:11 E:25 ||| JJ
mechanisms  ||| S:25 E:36 ||| NNS
of  ||| S:36 E:39 ||| IN
action ||| S:39 E:45 ||| NN
:  ||| S:45 E:47 ||| :
the  ||| S:47 E:51 ||| DT
role  ||| S:51 E:56 ||| NN
of  ||| S:56 E:59 ||| IN
Th1  ||| S:59 E:63 ||| CD
response  ||| S:63 E:72 ||| NN
Specific  ||| S:72 E:81 ||| JJ
immunotherapy  ||| S:81 E:95 ||| NNS
( ||| S:95 E:96 ||| -LRB-
SIT ||| S:96 E:99 ||| NNP
)  ||| S:99 E:101 ||| -RRB-
is  ||| S:101 E:104 ||| VBZ
the  ||| S:104 E:108 ||| DT
only  ||| S:108 E:113 ||| JJ
treatment  ||| S:113 E:123 ||| NN
able  ||| S:123 E:128 ||| JJ
to  ||| S:128 E:131 ||| TO
modify  ||| S:131 E:138 ||| VB
the  ||| S:138 E:142 ||| DT
natural  ||| S:142 E:150 ||| JJ
history  ||| S:150 E:158 ||| NN
of  ||| S:158 E:161 ||| IN
allergic  ||| S:161 E:170 ||| JJ
subjects ||| S:170 E:178 ||| NNS
.  ||| S:178 E:180 ||| .
Several  ||| S:180 E:188 ||| JJ
aspects  ||| S:188 E:196 ||| NNS
of  ||| S:196 E:199 ||| IN
the  ||| S:199 E:203 ||| DT
immunopathological  ||| S:203 E:222 ||| JJ
response  ||| S:222 E:231 ||| NN
modified  ||| S:231 E:240 ||| VBN
by  ||| S:240 E:243 ||| IN
sublingual  ||| S:243 E:254 ||| JJ
immunotherapy  ||| S:254 E:268 ||| NNS
( ||| S:268 E:269 ||| -LRB-
SLIT ||| S:269 E:273 ||| NNP
) ||| S:273 E:274 ||| -RRB-
,  ||| S:274 E:276 ||| ,
which  ||| S:276 E:282 ||| WDT
is  ||| S:282 E:285 ||| VBZ
an  ||| S:285 E:288 ||| DT
alternative  ||| S:288 E:300 ||| JJ
route  ||| S:300 E:306 ||| NN
of  ||| S:306 E:309 ||| IN
administration  ||| S:309 E:324 ||| NN
for  ||| S:324 E:328 ||| IN
SIT ||| S:328 E:331 ||| NNP
,  ||| S:331 E:333 ||| ,
have  ||| S:333 E:338 ||| VBP
been  ||| S:338 E:343 ||| VBN
investigated ||| S:343 E:355 ||| VBN
.  ||| S:355 E:357 ||| .
A  ||| S:357 E:359 ||| DT
shift  ||| S:359 E:365 ||| NN
from  ||| S:365 E:370 ||| IN
Th2-polarized  ||| S:370 E:384 ||| CD
immune  ||| S:384 E:391 ||| JJ
response  ||| S:391 E:400 ||| NN
toward  ||| S:400 E:407 ||| IN
Th1-oriented  ||| S:407 E:420 ||| CD
pattern  ||| S:420 E:428 ||| NN
has  ||| S:428 E:432 ||| VBZ
been  ||| S:432 E:437 ||| VBN
reported  ||| S:437 E:446 ||| VBN
after  ||| S:446 E:452 ||| IN
SLIT ||| S:452 E:456 ||| NNP
.  ||| S:456 E:458 ||| .
More  ||| S:458 E:463 ||| RBR
recently ||| S:463 E:471 ||| RB
,  ||| S:471 E:473 ||| ,
a  ||| S:473 E:475 ||| DT
crucial  ||| S:475 E:483 ||| JJ
role  ||| S:483 E:488 ||| NN
for  ||| S:488 E:492 ||| IN
a  ||| S:492 E:494 ||| DT
subpopulation  ||| S:494 E:508 ||| NN
of  ||| S:508 E:511 ||| IN
T  ||| S:511 E:513 ||| NN
cells  ||| S:513 E:519 ||| NNS
has  ||| S:519 E:523 ||| VBZ
been  ||| S:523 E:528 ||| VBN
evidenced ||| S:528 E:537 ||| VBN
:  ||| S:537 E:539 ||| :
T  ||| S:539 E:541 ||| NN
regulatory  ||| S:541 E:552 ||| JJ
cells  ||| S:552 E:558 ||| NNS
( ||| S:558 E:559 ||| -LRB-
Treg ||| S:559 E:563 ||| NNP
) ||| S:563 E:564 ||| -RRB-
.  ||| S:564 E:566 ||| .
Allergic  ||| S:566 E:575 ||| JJ
patients  ||| S:575 E:584 ||| NNS
have  ||| S:584 E:589 ||| VBP
a  ||| S:589 E:591 ||| DT
defect  ||| S:591 E:598 ||| NN
of  ||| S:598 E:601 ||| IN
Tregs ||| S:601 E:606 ||| NNP
,  ||| S:606 E:608 ||| ,
and  ||| S:608 E:612 ||| CC
SLIT  ||| S:612 E:617 ||| NNP
should  ||| S:617 E:624 ||| MD
be  ||| S:624 E:627 ||| VB
able  ||| S:627 E:632 ||| JJ
to  ||| S:632 E:635 ||| TO
induce  ||| S:635 E:642 ||| VB
a  ||| S:642 E:644 ||| DT
specific  ||| S:644 E:653 ||| JJ
Treg  ||| S:653 E:658 ||| JJ
response ||| S:658 E:666 ||| NN
.  ||| S:666 E:668 ||| .
This  ||| S:668 E:673 ||| DT
issue  ||| S:673 E:679 ||| NN
is  ||| S:679 E:682 ||| VBZ
very  ||| S:682 E:687 ||| RB
relevant  ||| S:687 E:696 ||| JJ
as  ||| S:696 E:699 ||| IN
the  ||| S:699 E:703 ||| DT
Treg-dependent  ||| S:703 E:718 ||| JJ
cytokines ||| S:718 E:727 ||| NN
,  ||| S:727 E:729 ||| ,
namely  ||| S:729 E:736 ||| RB
IL-10  ||| S:736 E:742 ||| CD
and  ||| S:742 E:746 ||| CC
TGF-beta ||| S:746 E:754 ||| JJ
,  ||| S:754 E:756 ||| ,
are  ||| S:756 E:760 ||| VBP
involved  ||| S:760 E:769 ||| VBN
in  ||| S:769 E:772 ||| IN
the  ||| S:772 E:776 ||| DT
regulation  ||| S:776 E:787 ||| NN
of  ||| S:787 E:790 ||| IN
IgG  ||| S:790 E:794 ||| JJ
and  ||| S:794 E:798 ||| CC
IgA  ||| S:798 E:802 ||| JJ
antibodies  ||| S:802 E:813 ||| JJ
production ||| S:813 E:823 ||| NN
.  ||| S:823 E:825 ||| .
Recent  ||| S:825 E:832 ||| JJ
evidence  ||| S:832 E:841 ||| NN
shows  ||| S:841 E:847 ||| NNS
that  ||| S:847 E:852 ||| IN
SLIT  ||| S:852 E:857 ||| NNP
is  ||| S:857 E:860 ||| VBZ
also  ||| S:860 E:865 ||| RB
able  ||| S:865 E:870 ||| JJ
of  ||| S:870 E:873 ||| IN
inducing  ||| S:873 E:882 ||| VBG
a  ||| S:882 E:884 ||| DT
Treg  ||| S:884 E:889 ||| JJ
response  ||| S:889 E:898 ||| NN
as  ||| S:898 E:901 ||| IN
detected  ||| S:901 E:910 ||| VBN
by  ||| S:910 E:913 ||| IN
IL-10  ||| S:913 E:919 ||| CD
production ||| S:919 E:929 ||| NN
.  ||| S:929 E:931 ||| .
IFNgamma  ||| S:931 E:940 ||| NNP
is  ||| S:940 E:943 ||| VBZ
a  ||| S:943 E:945 ||| DT
typical  ||| S:945 E:953 ||| JJ
Th1-dependent  ||| S:953 E:967 ||| CD
cytokine ||| S:967 E:975 ||| NNS
.  ||| S:975 E:977 ||| .
SLIT  ||| S:977 E:982 ||| NNP
may  ||| S:982 E:986 ||| MD
induce  ||| S:986 E:993 ||| VB
a  ||| S:993 E:995 ||| DT
significantly  ||| S:995 E:1009 ||| RB
increased  ||| S:1009 E:1019 ||| VBN
production  ||| S:1019 E:1030 ||| NN
of  ||| S:1030 E:1033 ||| IN
this  ||| S:1033 E:1038 ||| DT
cytokine  ||| S:1038 E:1047 ||| NN
and  ||| S:1047 E:1051 ||| CC
it  ||| S:1051 E:1054 ||| PRP
may  ||| S:1054 E:1058 ||| MD
be  ||| S:1058 E:1061 ||| VB
considered  ||| S:1061 E:1072 ||| VBN
as  ||| S:1072 E:1075 ||| IN
an  ||| S:1075 E:1078 ||| DT
early  ||| S:1078 E:1084 ||| JJ
marker  ||| S:1084 E:1091 ||| NN
of  ||| S:1091 E:1094 ||| IN
SLIT  ||| S:1094 E:1099 ||| NNP
response ||| S:1099 E:1107 ||| NN
.  ||| S:1107 E:1109 ||| .
Therefore ||| S:1109 E:1118 ||| RB
,  ||| S:1118 E:1120 ||| ,
also  ||| S:1120 E:1125 ||| RB
SLIT  ||| S:1125 E:1130 ||| NNP
is  ||| S:1130 E:1133 ||| VBZ
able  ||| S:1133 E:1138 ||| JJ
of  ||| S:1138 E:1141 ||| IN
exerting  ||| S:1141 E:1150 ||| VBG
the  ||| S:1150 E:1154 ||| DT
effects  ||| S:1154 E:1162 ||| NNS
on  ||| S:1162 E:1165 ||| IN
immune  ||| S:1165 E:1172 ||| JJ
response  ||| S:1172 E:1181 ||| NN
as  ||| S:1181 E:1184 ||| IN
well  ||| S:1184 E:1189 ||| RB
as  ||| S:1189 E:1192 ||| IN
the  ||| S:1192 E:1196 ||| DT
subcutaneous  ||| S:1196 E:1209 ||| JJ
route ||| S:1209 E:1214 ||| NN
.  ||| S:1214 E:1216 ||| .
